CO2021000914A2 - Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a - Google Patents

Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a

Info

Publication number
CO2021000914A2
CO2021000914A2 CONC2021/0000914A CO2021000914A CO2021000914A2 CO 2021000914 A2 CO2021000914 A2 CO 2021000914A2 CO 2021000914 A CO2021000914 A CO 2021000914A CO 2021000914 A2 CO2021000914 A2 CO 2021000914A2
Authority
CO
Colombia
Prior art keywords
methods
muscular dystrophy
treatment
recombinant adeno
associated virus
Prior art date
Application number
CONC2021/0000914A
Other languages
English (en)
Inventor
Zarife Sahenk
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of CO2021000914A2 publication Critical patent/CO2021000914A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se proporcionan productos y métodos para tratar la distrofia muscular de cinturas 2A. En los métodos, los virus adenoasociados recombinantes administran ADN que codifica una proteína con actividad de calpaína 3.
CONC2021/0000914A 2018-06-29 2021-01-28 Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a CO2021000914A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691934P 2018-06-29 2018-06-29
US201962865081P 2019-06-21 2019-06-21
PCT/US2019/039893 WO2020006458A1 (en) 2018-06-29 2019-06-28 Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a

Publications (1)

Publication Number Publication Date
CO2021000914A2 true CO2021000914A2 (es) 2021-02-08

Family

ID=67544319

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000914A CO2021000914A2 (es) 2018-06-29 2021-01-28 Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a

Country Status (15)

Country Link
US (1) US20210277362A1 (es)
EP (1) EP3814514A1 (es)
JP (1) JP2021528983A (es)
KR (1) KR20210028162A (es)
CN (1) CN112543810A (es)
AU (1) AU2019295779A1 (es)
BR (1) BR112020026853A2 (es)
CA (1) CA3105216A1 (es)
CL (1) CL2020003384A1 (es)
CO (1) CO2021000914A2 (es)
IL (1) IL279789A (es)
MX (1) MX2020014119A (es)
SG (1) SG11202012715UA (es)
TW (1) TW202020161A (es)
WO (1) WO2020006458A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257595A1 (en) 2020-06-15 2021-12-23 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery for muscular dystrophies
EP4108263A3 (en) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
USD1008419S1 (en) * 2021-06-14 2023-12-19 Jong Won Kim Vent valve of a wastewater drainage pipe
EP4198048A1 (en) 2021-12-16 2023-06-21 Genethon Calpain-3 gene transfer increase using modified itr sequences

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
AU688428B2 (en) 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
KR20000068501A (ko) 1996-09-06 2000-11-25 트러스티스 오브 더 유니버시티 오브 펜실바니아 재조합 아데노-관련 바이러스 지정 유전자 요법을 위한 방법
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1009808B1 (en) 1997-09-05 2012-12-05 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
WO2001083692A2 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
BR112018009954A2 (pt) * 2015-11-16 2018-11-13 Res Inst Nationwide Childrens Hospital materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias
CA3021057A1 (en) * 2016-04-15 2017-10-19 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy

Also Published As

Publication number Publication date
MX2020014119A (es) 2021-06-18
IL279789A (en) 2021-03-01
EP3814514A1 (en) 2021-05-05
AU2019295779A1 (en) 2021-01-28
CL2020003384A1 (es) 2021-07-23
TW202020161A (zh) 2020-06-01
SG11202012715UA (en) 2021-01-28
KR20210028162A (ko) 2021-03-11
CN112543810A (zh) 2021-03-23
CA3105216A1 (en) 2020-01-02
US20210277362A1 (en) 2021-09-09
JP2021528983A (ja) 2021-10-28
BR112020026853A2 (pt) 2021-04-20
WO2020006458A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
CO2021000914A2 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
NZ737757A (en) Peptide oligonucleotide conjugates
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
PE20181338A1 (es) Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2020004005A (es) Terapias genicas para los trastornos lisosomales.
EA202091615A1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания
EA202091995A1 (ru) Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
CO2018000171A2 (es) Metodos de purificacion y/o inactividad viral
BR112017023425A2 (pt) combinações terapêuticas de terapias antivirais e anti-inflamatórias
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου
AR115647A1 (es) Productos y métodos con virus adenoasociados recombinantes para el tratamiento de la distrofia muscular de extremidades y cintura de tipo 2a
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
EP4108263A3 (en) Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CO2019000942A2 (es) Composición y uso de un péptido
EA202190155A1 (ru) Продукты на основе рекомбинантных аденоассоциированных вирусов и способы для лечения тазово-плечевой мышечной дистрофии типа 2а
EA202191503A1 (ru) Комбинированные терапии для мдс высокого и очень высокого риска